In the afternoon of 1 June 2020, Insight Lifetech successfully held a premarketing conference on its TruePhysio^®pressure microcatheter and VivoCardio^®FFR system in the auditorium of Zhongshan Hospital Affiliated to Fudan University (Shanghai, China).  The Chinese cardiovascular community welcomed the long awaited first domestic FFR measurement product, which is allso the first MEMS-sensor rapid-exchange FFR measurement system worldwide. In particular, the TruePhysio^®rapid-exchange pressure microcatheter, derived from an innovative CathMEMS^TM proprietary design, has a 0.0205'' ultra-small profile and is compatible with any 0.014” guidewire for accurate and time-saving measurement of FFR.

The conference was honored by the presence of many internationally renowned cardiologists——including Prof. Dr. Junbo Ge, former president of the Chinese Society pf Cardiology, Academician of the Zhongshan Hospital Affiliated to Fudan University, Prof. Dr. Emanuele Barbato,  President-Elect EAPCI (European Association of Percutaneous Cardiovascular Interventions), Prof. Dr. Yong Huo, Head of Cardiology Department of Peking University First Hospital, Prof. Dr. Wang Jian'an, Head of Cardiology Department of the Second Affiliated Hospital of Zhejiang University School of Medicine, Prof. Dr. Chen Jiyan, Head of Cardiology Department of Guangdong Provincial People's Hospital, and etc., Along with the product premarketing release ceremony, an Academic Summit focusing on the features and clinical applications of FFR pressure microcatheter was held, through which cardiologists lively discussed the significant clinical value and great potential of this new FFR measurement tool with newly generated clinical results and exciting cases.

Insight Lifetech FFR Measurement System Premarketing Ribbon Cutting Ceremony in Shanghai

Relying on CathMEMS^TM and other proprietary innovative technologies with global intellectual property rights, the Insight Lifetech's TruePhysio^® Microcatheter and VivoCardio^® console enable physicians to perform precision diagnosis of functional ischemia in coronary artery disease and identify the precise location of ischemia-causing lesion that requires percutaneous coronary intervention treatment and provide more convenient and rapid measurement. Its official launch not only won the high recognition of cardiologists at home and abroad, but also demonstrated lindustry-leading innovative capacities of Chinese medical technology enterprises in the field of cardiovascular intervention. With additional innovative products in the pipeline. Insight Lifetech will consistently pursue its mission to transform healthcare through innovation and quality.